| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | msrB |
| Uniprot No | Q9Y3D2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-182aa |
| 氨基酸序列 | MARLLWLLRGLTLGTAPRRAVRGQAGGGGPGTGPGLGEAGSLATCELPLAKSEWQKKLTPEQFYVTREKGTEPPFSGIYLNNKEAGMYHCVCCDSPLFSSEKKYCSGTGWPSFSEAHGTSGSDESHTGILRRLDTSLGSARTEVVCKQCEAHLGHVFPDGPGPNGQRFCINSVALKFKPRKH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于msrB重组蛋白的3篇参考文献概要，供参考：
1. **文献名称**：*"Expression and Characterization of Recombinant Methionine Sulfoxide Reductase B from Arabidopsis thaliana"*
**作者**：Cheng et al.
**摘要**：研究通过在大肠杆菌中异源表达拟南芥MSRB蛋白，优化纯化条件并获得高纯度重组蛋白;证实其可有效还原游离型甲硫氨酸亚砜，并在体外抗氧化实验中表现出活性依赖半胱氨酸残基。
2. **文献名称**：*"Cloning and Functional Analysis of a Novel msrB Gene in Deinococcus radiodurans"*
**作者**：Li et al.
**摘要**：克隆耐辐射奇球菌中的msrB基因，构建重组质粒并在大肠杆菌中表达;重组蛋白显示对氧化损伤的保护作用，并通过定点突变验证关键催化位点对酶活性的必要性。
3. **文献名称**：*"Biotechnological Production of Recombinant msrB for Therapeutic Applications"*
**作者**：Park & Kim
**摘要**：开发了一种基于毕赤酵母表达系统的重组MSRB规模化生产工艺，证明其可高效分泌表达且具有稳定酶活性，为治疗氧化应激相关疾病提供了潜在药用蛋白来源。
---
注：以上文献信息为示例性质，实际文献需通过数据库(如PubMed、Web of Science)检索确认。建议结合具体研究方向补充关键词(如物种、表达系统或应用场景)进行精准检索。
Methionine sulfoxide reductase B (MsrB) is a critical enzyme involved in the repair of oxidatively damaged proteins, specifically reducing methionine sulfoxide residues back to methionine. This post-translational modification is essential for maintaining protein function and cellular homeostasis under oxidative stress conditions. As part of the methionine sulfoxide reductase (Msr) system, MsrB complements MsrA by specifically targeting the R-form of methionine sulfoxide, while MsrA acts on the S-form. This redox repair mechanism plays a vital role in mitigating oxidative damage linked to aging, neurodegenerative diseases, and various inflammatory conditions.
Recombinant MsrB proteins are engineered through genetic cloning and heterologous expression systems, typically using E. coli, yeast, or mammalian cell cultures. The recombinant approach allows for high-yield production, structural modification, and functional optimization of the enzyme. Studies have revealed that MsrB exists in multiple isoforms across species, with human MsrB1 being a selenocysteine-containing enzyme localized to the nucleus and cytosol, while MsrB2 resides in mitochondria.
Current research focuses on its therapeutic potential, particularly in age-related pathologies and protein aggregation diseases. Recombinant MsrB has shown promise in experimental models for Alzheimer's disease, cataracts, and cardiovascular disorders by reducing oxidative protein damage. In biotechnology applications, it serves as a stabilizing agent for therapeutic proteins vulnerable to oxidation. Recent advances in protein engineering aim to enhance its catalytic efficiency and stability through site-directed mutagenesis and fusion protein strategies. The development of recombinant MsrB continues to provide valuable tools for both basic redox biology research and translational medical applications.
×
